Associations - Torisel (temsirolimus)

No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	temsirolimus Sensitive: C2 – Inclusion Criteria temsirolimus Sensitive : C2	temsirolimus Sensitive: C2 – Inclusion Criteria temsirolimus Sensitive : C2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3	neratinib + temsirolimus Sensitive: C3 – Early Trials neratinib + temsirolimus Sensitive : C3
KIAA1549-BRAF fusion	Soft Tissue Sarcoma	KIAA1549-BRAF fusion	Soft Tissue Sarcoma	bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials bevacizumab + sorafenib + temsirolimus Sensitive : C3	bevacizumab + sorafenib + temsirolimus Sensitive: C3 – Early Trials bevacizumab + sorafenib + temsirolimus Sensitive : C3
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
PTEN deletion	Breast Cancer	PTEN deletion	Breast Cancer	bevacizumab + temsirolimus Sensitive: C3 – Early Trials bevacizumab + temsirolimus Sensitive : C3	bevacizumab + temsirolimus Sensitive: C3 – Early Trials bevacizumab + temsirolimus Sensitive : C3
AKT1 mutation	Endometrial Cancer	AKT1 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC1 mutation	Endometrial Cancer	TSC1 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Endometrial Cancer	TSC2 mutation	Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
ARID1B deletion	Mantle Cell Lymphoma	ARID1B deletion	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
DLGAP2 deletion	Mantle Cell Lymphoma	DLGAP2 deletion	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
BIRC3 mutation	Mantle Cell Lymphoma	BIRC3 mutation	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
MTOR mutation	Renal Cell Carcinoma	MTOR mutation	Renal Cell Carcinoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC1 mutation	Renal Cell Carcinoma	TSC1 mutation	Renal Cell Carcinoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 mutation	Renal Cell Carcinoma	TSC2 mutation	Renal Cell Carcinoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
PBRM1 mutation + SETD2 mutation	Renal Cell Carcinoma	PBRM1 mutation + SETD2 mutation	Renal Cell Carcinoma	temsirolimus + axitinib Sensitive: C4 – Case Studies temsirolimus + axitinib Sensitive : C4	temsirolimus + axitinib Sensitive: C4 – Case Studies temsirolimus + axitinib Sensitive : C4
KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4
KIT L576P	Mucosal Melanoma	KIT L576P	Mucosal Melanoma	temsirolimus Resistant: C4 – Case Studies temsirolimus Resistant : C4	temsirolimus Resistant: C4 – Case Studies temsirolimus Resistant : C4
KIAA1549-BRAF fusion	Melanoma	KIAA1549-BRAF fusion	Melanoma	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4
TSC1 deletion	Renal Cell Carcinoma	TSC1 deletion	Renal Cell Carcinoma	temsirolimus Sensitive: C4 – Case Studies temsirolimus Sensitive : C4	temsirolimus Sensitive: C4 – Case Studies temsirolimus Sensitive : C4
FBXW7 R222X	Colorectal Cancer	FBXW7 R222X	Colorectal Cancer	bevacizumab + cetuximab + temsirolimus Sensitive: C4 – Case Studies bevacizumab + cetuximab + temsirolimus Sensitive : C4	bevacizumab + cetuximab + temsirolimus Sensitive: C4 – Case Studies bevacizumab + cetuximab + temsirolimus Sensitive : C4
PIK3CA mutation	Thyroid Gland Carcinoma	PIK3CA mutation	Thyroid Gland Carcinoma	temsirolimus + MK-2206 Sensitive: D – Preclinical temsirolimus + MK-2206 Sensitive : D	temsirolimus + MK-2206 Sensitive: D – Preclinical temsirolimus + MK-2206 Sensitive : D
PIK3CA mutation	Endometrial Cancer	PIK3CA mutation	Endometrial Cancer	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D	temsirolimus Sensitive: D – Preclinical temsirolimus Sensitive : D

Torisel (temsirolimus)

Associations
(37)

Associations
(37)

Torisel (temsirolimus)

Associations(37)

Associations(37)

Associations
(37)

Associations
(37)